Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC

NCT07549100 · clinicaltrials.gov ↗

RECRUITING

Status

30

Enrollment

OTHER_GOV

Sponsor class

Conditions

Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Tislelizumab Plus Chemotherapy

Sponsor

Shandong Provincial Hospital